FDA Inspection 1270490 — Kai Huang
The FDA completed an inspection of Kai Huang on May 16, 2025 in Wuxi. The inspection was classified VAI (Voluntary Action Indicated — objectionable conditions or practices were found, but the agency is not prepared to take or recommend any administrative or regulatory action). Product area: Drugs.
Inspection Details
- Classification
- Voluntary Action Indicated (VAI)
- End Date
- May 16, 2025
- Fiscal Year
- 2025
- Product Type
- Drugs
- Project Area
- Bioresearch Monitoring
- Location
- Wuxi (China)
Additional Details
Clinical BA/BE